Novartis : publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
Continuous Kesimpta® treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of...
Source: marketscreener.com